Contineum Therapeutics Inc (CTNM)

May 25, 2026

Contineum Therapeutics (CTNM) Declines 3.55%, Testing Key Support at $13.17Swing Trade Setups - Newser

May 25, 2026

May 25, 2026

Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High? - Yahoo Finance Singapore

May 25, 2026

May 25, 2026

Contineum Therapeutics Inc. (CTNM) Q1 2026 Earnings: Clinical-Stage Biotech Reports Narrower Loss, Shares DipProduct Revenue Analysis - Newser

May 25, 2026

May 24, 2026

CTNM Q1 2026 Earnings: Narrower-than-Expected Loss Drives Strong EPS Surprise, but Shares SlipExpert Market Insights - Newser

May 24, 2026

May 22, 2026

Contineum Therapeutics, Inc.Common stock (CTNM) Stock Price, News, Quote & History - FinancialContent

May 22, 2026

May 22, 2026

CTNM Q1 2026 Earnings: Significant EPS Beat Amid Pipeline Progress, Stock Slightly DownViral Trade Signals - Newser

May 22, 2026

May 22, 2026

Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential - Yahoo Finance

May 22, 2026

May 17, 2026

Contineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety Bar - MSN

May 17, 2026

May 15, 2026

RA Capital affiliates report 1.296M shares of Contineum (CTNM) - Stock Titan

May 15, 2026

May 15, 2026

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

May 15, 2026

May 15, 2026

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? - Yahoo Finance

May 15, 2026

May 15, 2026

Balyasny Group (CTNM) reports 2.42M shares via ADMF, ~7.40% stake - Stock Titan

May 15, 2026

May 14, 2026

Morgan Stanley Raises Price Target on Contineum Therapeutics to $16 From $14, Keeps Equalweight Rating - Moomoo

May 14, 2026

May 14, 2026

Contineum Therapeutics, Inc. Stock 12‑Month Price Target Raised to $22.33, Implies 58% Upside - TradingView

May 14, 2026

May 14, 2026

Morgan Stanley Maintains Contineum Therapeutics(CTNM.US) With Hold Rating, Raises Target Price to $16 - Moomoo

May 14, 2026

May 13, 2026

Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference - BioSpace

May 13, 2026

May 12, 2026

Stream Contineum’s 2026 RBC Global Healthcare Conference talk live - Stock Titan

May 12, 2026

May 12, 2026

Ring Energy Announces Proposed Public Offering of Common Stock - Weekly Voice

May 12, 2026

May 12, 2026

TradingKey - TradingKey

May 12, 2026

May 12, 2026

Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference - BioSpace

May 12, 2026

May 11, 2026

Stifel Nicolaus Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail

May 11, 2026

May 11, 2026

RBC Capital Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - MSN

May 11, 2026

May 11, 2026

Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

May 11, 2026

May 10, 2026

Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet - MSN

May 10, 2026

May 09, 2026

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Entrada Therapeutics Inc (TRDA) and Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail

May 09, 2026

May 08, 2026

CTNM SEC FilingsContineum Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan

May 08, 2026

May 07, 2026

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Contineum Therapeutics, Inc. Class A (CTNM) and Exelixis (EXEL) - The Globe and Mail

May 07, 2026

May 07, 2026

Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Contineum Therapeutics, Inc. Class A (CTNM) and Schrodinger (SDGR) - The Globe and Mail

May 07, 2026

May 06, 2026

Document - SEC.gov

May 06, 2026

May 06, 2026

Contineum Therapeutics, Inc. Q1 2026 Financial Report: Earnings, Clinical Pipeline Progress, and Forward-Looking Statements 14 - Minichart

May 06, 2026

May 06, 2026

Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones - BioSpace

May 06, 2026

May 05, 2026

Contineum Therapeutics Sees Funding Sufficient Through Mid-2029 >CTNM - Moomoo

May 05, 2026

May 05, 2026

Contineum (NASDAQ: CTNM) Q1 loss narrows, cash reaches $246.3M - Stock Titan

May 05, 2026

May 05, 2026

Chronic pain data and cash runway to 2029 for Contineum (NASDAQ: CTNM) - Stock Titan

May 05, 2026

May 05, 2026

Contineum Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 05, 2026

May 04, 2026

Contineum Therapeutics (NASDAQ:CTNM) Shares Up 7.5%Time to Buy? - MarketBeat

May 04, 2026

May 01, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

May 01, 2026

May 01, 2026

Contineum Therapeutics CSO Daniel Lorrain sells $54,694 in stock - Investing.com

May 01, 2026

May 01, 2026

Contineum Therapeutics CSO Daniel Lorrain sells $54,694 in stock By Investing.com - Investing.com South Africa

May 01, 2026

May 01, 2026

Contineum (NASDAQ: CTNM) CSO trims stake under 10b5-1 plan - Stock Titan

May 01, 2026

May 01, 2026

CTNM (NASDAQ: CTNM) affiliate reports multiple 10b5-1 sales by Daniel Lorrain - Stock Titan

May 01, 2026

May 01, 2026

Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Weekly Voice

May 01, 2026

May 01, 2026

Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain - BioSpace

May 01, 2026

Apr 30, 2026

Contineum reports phase 1b trial results for chronic pain drug By Investing.com - Investing.com South Africa

Apr 30, 2026

Apr 30, 2026

Contineum Therapeutics Reports Positive Phase 1b Data for Chronic Pain Treatment - Moomoo

Apr 30, 2026